Skip to main
ZVSA
ZVSA logo

ZVSA Stock Forecast & Price Target

ZVSA Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ZyVersa Therapeutics Inc. exhibits a promising outlook due to its innovative drug development platforms, particularly the Cholesterol Efflux Mediator™ VAR 200 and the monoclonal antibody inflammasome ASC inhibitor IC 100, which target chronic renal and inflammatory diseases with significant unmet medical needs. The recent $2.7 million cash influx from warrant exercises reflects strong investor interest and confidence in the company's clinical programs, with a noted increase in trading volume suggesting robust market activity. Additionally, the company has improved its probability of success for VAR 200 in treating diabetic kidney disease (DKD) to 25%, supported by strong preclinical data and the approval of a Phase 2a clinical trial protocol, indicating actionable progress in the company's therapeutic development pipeline.

Bears say

ZyVersa Therapeutics reported a significant net loss of $106.2 million for 2023, translating to a loss of $108.97 per share, which raises concerns about its financial viability. The company faces multiple risks, including potential clinical trial failures, challenges in securing regulatory approvals for its drug candidates VAR 200 and IC 100, and the possibility of limited commercial opportunities stemming from market size and competition. Additionally, issues such as insufficient funding, potential dilution from future equity financing, and the threat of delisting from Nasdaq cast further doubt on the company's outlook and operational stability.

ZVSA has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ZyVersa Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ZyVersa Therapeutics Inc (ZVSA) Forecast

Analysts have given ZVSA a Strong Buy based on their latest research and market trends.

According to 1 analysts, ZVSA has a Strong Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ZyVersa Therapeutics Inc (ZVSA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.